MENU
CYTK
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

CYTK stock forecast, quote, news & analysis

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining... Show more

Industry: #Biotechnology
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
Oct 21, 2026

Cytokinetics (CYTK) Stock Analysis: Myqorzo's Global Launch and Label Expansion Take Center Stage

Key Takeaways

  • Cytokinetics shares traded near $63.95 as of the latest close, down roughly 5% from about $67.56 roughly 30 calendar days earlier.
  • The pullback reflects broader pressure on commercial-stage biotech names rather than a change in the company's core fundamentals.
  • MYQORZO (aficamten), its first commercial product, is now approved in the U.S., European Union, United Kingdom, China, and Canada for symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
  • Positive Phase 3 results from ACACIA-HCM in non-obstructive HCM (nHCM) met both primary endpoints, supporting a potential label expansion.
  • Wall Street analysts largely maintain Buy or Outperform ratings, with several price targets well above current trading levels.

Current Market Snapshot

Cytokinetics (CYTK) has spent recent weeks consolidating within a relatively narrow band, with its latest close near $63.95 compared with roughly $67.56 about 30 days prior — a decline of approximately 5%. The move has been incremental rather than driven by a single event, consistent with the stock trading near the lower end of its recent range. Broader sentiment toward commercial-stage biotech names has been cautious, even for companies reporting encouraging launch metrics, which has contributed to modest downward drift in the share price.

Cytokinetics (CYTK) Business Overview and Competitive Position

Cytokinetics is a specialty cardiovascular biopharmaceutical company based in South San Francisco, California, with more than two decades of expertise in muscle biology. The company discovers and develops small molecules that modulate cardiac muscle contractility, targeting diseases of cardiac muscle dysfunction.

Its lead asset, MYQORZO (aficamten), is an allosteric and reversible cardiac myosin inhibitor designed to reduce cardiac contractility and left ventricular outflow tract obstruction in patients with oHCM. Following FDA approval in December 2025, the company has executed a staged global commercialization strategy, with launches in the U.S. and Europe (beginning in Germany) during 2026. The pipeline also includes omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction, positioning Cytokinetics as a leader in cardiac myosin biology.

Recent Developments Driving CYTK

Several verified developments have shaped investor sentiment over the last 30 days. On October 19, 2026, the company announced Health Canada approval of MYQORZO for adults with symptomatic oHCM — its fifth regulatory approval in under a year, following clearances in the U.S., China, the European Union, and the United Kingdom. This milestone reinforces the drug's expanding global footprint.

On the clinical front, full results from ACACIA-HCM, the pivotal Phase 3 trial of aficamten in non-obstructive HCM, were presented at the ESC Congress 2026 and published in The New England Journal of Medicine. The trial met both dual primary endpoints, showing statistically significant improvements in patient-reported and physician-assessed measures, and supports a potential label expansion into nHCM.

Analyst activity has remained constructive. RBC Capital raised its price target to $113 while maintaining an Outperform rating, H.C. Wainwright reiterated a Buy rating with a $140 target, and Needham maintained a Buy rating with a $112 target. Despite these positive signals, shares have lagged, partly reflecting caution ahead of the MAPLE-HCM supplemental new drug application (sNDA) decision and general risk-off positioning in biotech.

Trending AI Robots

Tickeron's Trending AI Robots page curates a selection of automated trading systems drawn from a much larger universe of AI-driven bots that monitor thousands of tickers. Only the top-performing and most relevant robots appear in this featured section, giving traders a focused view of strategies that are currently demonstrating notable results. Each robot varies in trading strategy, holding timeframe, and performance metrics, so the page offers a convenient way to compare different approaches side by side. Traders interested in data-driven market analysis can explore the section to see which AI strategies are generating momentum.

2026 Outlook and What Investors Should Watch

Investors are likely to focus on several catalysts through the remainder of 2026. The FDA has assigned a target action date of November 14, 2026 for the MAPLE-HCM sNDA, which seeks to expand aficamten's label based on its superiority over metoprolol as monotherapy. A favorable decision could broaden the addressable market and reinforce the drug's competitive differentiation.

Commercial execution remains central, with attention on U.S. prescription trends, European launch progress, and future market access in Canada and other regions. Continued data readouts across the pipeline, including ACACIA-HCM follow-up analyses and the ongoing CEDAR-HCM pediatric study, could further shape sentiment. Broader macroeconomic conditions, biotech sector risk appetite, and financing dynamics also remain relevant variables. As a company transitioning from clinical-stage to commercial-stage, Cytokinetics' ability to sustain revenue growth while managing operating expenses will be closely monitored.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for CYTK with price predictions
Nov 20, 2026

CYTK's Indicator enters downward trend

The Aroon Indicator for CYTK entered a downward trend on November 19, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 173 similar instances where the Aroon Indicator formed such a pattern. In 152 of the 173 cases the stock moved lower. This puts the odds of a downward move at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYTK as a result. In 78 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for CYTK turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 44 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.

The 50-day moving average for CYTK moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYTK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +6.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYTK advanced for three days, in 212 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

CYTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. CYTK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 83 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-43.024) is normal, around the industry mean (3.596). P/E Ratio (-7.436) is within average values for comparable stocks, (-1.186). CYTK's Projected Growth (PEG Ratio) (82.230) is slightly higher than the industry average of (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (443.347).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a company which engages in discovery and development of small molecule drug therapeutics

Industry Biotechnology

Industry
Biotechnology
Address
350 Oyster Point Boulevard
Phone
+1 650 624-3000
Employees
673
Web
https://www.cytokinetics.com
Cytokinetics (CYTK) Stock Analysis: Myqorzo's Global Launch and Label Expansion Take Center Stage